For more than 50 years the Developmental Therapeutics Program (DTP) at NCI has successfully guided late-stage preclinical drug candidates through the final steps of development to first-in-human studies. DTP has been involved in the discovery or development of more than 70% of the anticancer therapeutics on the market today. The Cancer Therapy Evaluation Program (CTEP) houses NCI’s primary program for clinical evaluation of new anticancer treatments, and provides and tracks experimental agents for clinical trials run by other NCI branches.
Both DTP and CTEP will provide integrated support to move NExT drug discovery and development projects from preclinical to clinical development. Resources for Phase 0 evaluation through exploratory INDs are also available to NExT projects.